
Please try another search
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Name | Age | Since | Title |
---|---|---|---|
George W. Sledge | 73 | 2014 | Member of Scientific Advisory Board |
Dennis G. Podlesak | 67 | 2008 | Independent Chairman |
Julie R. Brahmer | - | 2015 | Member of Scientific Advisory Board |
Pierre Legault | 65 | 2017 | Independent Director |
Hope S. Rugo | - | 2016 | Member of Scientific Advisory Board |
Michael A. Metzger | 54 | 2015 | CEO & Director |
Jedd D. Wolchok | - | 2016 | Member of Scientific Advisory Board |
Samir N. Khleif | 61 | 2016 | Member of Scientific Advisory Board |
Keith A. Katkin | 54 | 2017 | Independent Director |
Lisa M. Coussens | - | 2017 | Member of Scientific Advisory Board |
Ronald M. Evans | 76 | 2016 | Co-Founder, Advisor and Chair of Scientific Advisory Board |
Joseph Paul Eder | - | 2016 | Member of Scientific Advisory Board & Chief Medical Officer |
Jennifer A. Jarrett | 54 | 2018 | Independent Director |
Martin H. Huber | 64 | 2021 | Independent Director |
Aleksandra Rizo | 50 | 2024 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review